BACKGROUND. The clinical management of chronic hepatitis B virus (HBV) patients is based exclusively on virological parameters that cannot independently determine in which patients nucleos(t)ide-analogue (NUC) therapy can be safely discontinued. NUCs efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation can be associated with virological and biochemical relapse and, consequently, therapy in the majority is life-long.

中文翻译：

---

核苷酸（t）-类似物治疗终止后，乙肝病毒特异性T细胞与病毒控制有关

背景。慢性乙型肝炎病毒（HBV）患者的临床管理完全基于无法独立确定可以安全终止核苷酸（t）-类似物（NUC）治疗的患者的病毒学参数。NUC有效抑制病毒复制，但不能消除HBV。因此，治疗中止可能与病毒学和生化复发有关，因此，大多数治疗是终生的。